



QR Pharma to Present at 11th Annual World Pharma Congress

Berwyn, PA, May 29, 2012 [QR Pharma, Inc.](#) (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders, announced today that Dr. Maria Maccacchini, QR's chief executive officer, will speak at Cambridge Healthtech Institute's 11th Annual World Pharma Congress, in Philadelphia, PA. Dr. Maccacchini will present "Microglia Activation in the Alzheimer Brain; Normalization by Posiphen®". The session will be held on Wednesday, June 6, 2012, at 10:10 AM at Loews Philadelphia Hotel, Philadelphia, PA.

About Posiphen® QR's lead compound, [Posiphen®](#), is a small orally active compound with high blood brain barrier permeability. Posiphen reduces the levels of toxic proteins in the brains of patients with neurodegenerative disorders back to the levels found in normal healthy volunteers. By normalizing brain levels of alpha synuclein, beta amyloid and tau, it provides an avenue to treat Alzheimer's and Parkinson's disease early so as to prevent the onset or diminish the severity of cognitive decline. Since neurotoxic proteins cause inflammation in the brain, lowering their levels reduces inflammatory factors and lowers inflammation.

About QR Pharma, Inc. Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders. QR currently has three product development programs - Posiphen for early stage Alzheimer's and Parkinson's disease, and BNC for advanced Alzheimer's disease. For more information on QR Pharma, please visit the company's website, www.qrpharma.com.

Contact: Maria Maccacchini, CEO

Tel: 610 727 3910

Maccacchini@qrpharma.com

www.qrpharma.com